ZYNE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 spal. 2023 @ 23:00):

Stats
Šios dienos apimtis	861 742
Vidutinė apimtis	1.04M
Rinkos kapitalizacija	70.12M
EPS	$-0.210 ( Q2 \| 2023-08-14 )
Kita pelno data	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.646 (Sector) 42.63 (Industry) 0
ATR14	$0.0400 (3.08%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2023-10-10	Jones Kenneth T	Buy	30 000	Common Stock
2023-10-10	Jones Kenneth T	Sell	40 520	Common Stock
2023-10-10	Jones Kenneth T	Sell	75 000	Common Stock
2023-10-10	Jones Kenneth T	Sell	21 250	Stock Option (Right to Buy)
2023-10-10	Stephenson Pamela	Sell	27 954	Common Stock

INSIDER POWER
-53.44
Last 100 transactions
Buy: 1 916 312 \| Sell: 5 402 740

Tūris Koreliacija

Ilgas: 0.26 (neutral)

Trumpas: -0.55 (weak negative)

Signal:(58.623) Neutral

Zynerba Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
JUPW	0.908
NATI	0.847
BIOS	0.817

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Zynerba Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.62
( weak negative )

0.53
( weak )

0.00
( neutral )

-0.23
( neutral )

-0.68
( moderate negative )

0.59
( weak )

Zynerba Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.820

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.820

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.950

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.900

Financial Reports:

No articles found.

Zynerba Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.